A randomized, double-blind, placebo-controlled, phase 2, 6-month study to evaluate the safety, tolerability and exploratory efficacy of CT1812 in subjects with mild to moderate Dementia with Lewy Bodies.
Study of CT1812 in Patients with Dementia with Lewy Bodies (DLB)
Sponsor: Cognition Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAU1807
U.S. Govt. ID: NCT05225415
Contact: Katrina Cuasay: / kc2305@cumc.columbia.edu
Additional Study Information: This study is of a drug called CT1812, that is being evaluated as a possible treatment for Dementia with Lewy Bodies. In this study, which is carried out at multiple sites in the country, participants receive either CT1812 at one of two doses or placebo. The duration of the study is up to about 35 weeks. Participants receive blood tests, cerebrospinal fluid testing, pen and paper tests, and an MRI scan as part of the study procedures.
Lawrence Honig, MD, PhD
Do You Qualify?
Are you between the ages of 50-85? Yes No
Have you been diagnosed with mild to moderate Dementia with Lewy Bodies (DLB)? Yes No
Do you have a caregiver/study partner who is able to attend all study visits and participate in some study assessments? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Katrina Cuasay